SLC5A2 and Cirrhosis: Given the lack of current data on the safety or efficacy of SGLT-2 inhibitors in patients with cirrhosis, we hypothesized that these agents were associated with a reduced risk of serious liver events in patients with cirrhosis on diuretic therapy.